NATURAL HOLISTIC MEDICINE BLOG - People who have survived sepsis do not respond to vaccines in the same way as the general population, a finding that challenges current medical standards. This critical revelation, stemming from recent clinical trial results, suggests an urgent need to rethink post-sepsis care protocols to better protect vulnerable patients.
Understanding the VACIRiSS Trial Methodology
The VACIRiSS trial, spearheaded by King’s College London and Guy’s and St Thomas’ NHS Foundation Trust, was designed to investigate this specific medical phenomenon. Funded by the National Institute for Health and Care Research (NIHR), the study sought to determine if existing vaccination programmes effectively reduced the risk of future infections in adults who had survived sepsis.
In this controlled trial, 214 sepsis survivors were randomly assigned to receive either the PCV13 vaccine or a placebo injection. Researchers monitored these participants for a full year to track incidents of re-hospitalisation related to new infections or mortality.
The Reality of Sepsis and Immune System Alteration
Sepsis is defined as a violent misfiring of the body's immune response to bacterial, viral, or fungal infections. When not treated rapidly, this condition causes the failure of vital organs and often leads to death if medical intervention is delayed.
Globally, it is estimated that approximately 166 million sepsis cases occur each year, resulting in 21 million deaths annually. Of the 145 million patients who survive these acute episodes, many are left with a weakened or permanently altered immune system.
Clinical Findings and Disappointing Outcomes
The results of the VACIRiSS trial were published in the journal Science Translational Medicine, providing a sobering look at post-recovery health. The study found that the PCV13 vaccine, which typically protects the general population from pneumonia and meningitis, failed to reduce future infection or re-hospitalisation risks in sepsis survivors.
While blood tests indicated that many participants did generate some level of immune response, the effectiveness of these responses varied wildly. These differences were directly linked to underlying factors, including the patient's age, body weight, sex, and the severity of their immune system alteration prior to vaccination.
Implications for NHS Care and Long-Term Health
The long-term health impacts of sepsis survivors currently do not receive sufficient attention within the healthcare landscape, particularly in the UK. Data reveals that one in three sepsis survivors are re-hospitalised within 90 days, with the majority of these admissions resulting from secondary infections.
Furthermore, one in six patients are no longer alive by the end of the first year following their recovery from a sepsis event. Despite these alarming statistics, there is currently no routine, long-term follow-up care for sepsis survivors provided by the NHS.
Future Directions in Post-Sepsis Research
Professor Shankar-Hari, who serves as the Director of the King’s Health Partners’ Centre for Critical Illness Research, emphasizes that more work is required to understand why immune responses are altered. His ongoing efforts aim to advance medical understanding of the immune system in critical illnesses and improve the diagnosis, management, and treatment of sepsis.
The research findings suggest that established, one-size-fits-all vaccination programmes may need to be modified to provide better protection for this specific population. Investing in targeted post-sepsis care and continued research is essential to improve long-term health outcomes for these millions of vulnerable individuals worldwide.
Frequently Asked Questions (FAQ)
What is the primary finding of the VACIRiSS trial?
The trial found that sepsis survivors do not respond to vaccines in the same way as the general population, and that the PCV13 vaccine failed to reduce the risk of future infections or re-hospitalisations in this specific group.
Why are sepsis survivors at higher risk for future infections?
Sepsis survivors often have a weakened or altered immune system due to the systemic damage caused during their initial sepsis episode, which makes them more susceptible to subsequent infections.
What is the current standard of care for sepsis survivors regarding vaccinations?
Currently, there is no standardized, routine long-term follow-up care for sepsis survivors in the NHS, and established vaccination programmes are not yet tailored to address the unique immunological needs of this population.
What factors influenced the varied vaccine responses in the study?
The study linked the varied immune responses to several factors, including the age of the participant, their body weight, their sex, and the pre-existing level of immune system alteration before they received the vaccine.
Comments